-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Lersivirine
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/473921-12-9.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 473921-12-9 |
| Description | Lersivirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for the treatment of HIV-1 infection. It prevents HIV from entering the nucleus of healthy CD4 cells, which prevents the cells from producing new virus and decreases the amount of virus in the body. |
Product Information
| Synonyms | UK-453061; UK453061; UK 453061; UK-453,061; UK453,061; UK 453,061;Lersivirine |
| IUPAC Name | 5-[3,5-diethyl-1-(2-hydroxyethyl)pyrazol-4-yl]oxybenzene-1,3-dicarbonitrile |
| Molecular Weight | 310.35 |
| Molecular Formula | C17H18N4O2 |
| Canonical SMILES | CCC1=C(C(=NN1CCO)CC)OC2=CC(=CC(=C2)C#N)C#N |
| InChI | InChI=1S/C17H18N4O2/c1-3-15-17(16(4-2)21(20-15)5-6-22)23-14-8-12(10-18)7-13(9-14)11-19/h7-9,22H,3-6H2,1-2H3 |
| InChIKey | MCPUZZJBAHRIPO-UHFFFAOYSA-N |
| Boiling Point | 455.4±45.0 °C at 760 mmHg |
| Flash Point | 229.2±28.7 °C |
| Purity | >98% |
| Density | 1.2±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : 50 mg/mL(161.11 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 3 mg/mL (9.67 mM); Clear solution |
| Appearance | Light yellow to khaki (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 456 |
| Exact Mass | 310.14297583 |
| Index Of Refraction | 1.595 |
| In Vitro | Lersivirine demonstrates excellent activity against large panels of wild type and drug-resistant HIV consistent with the encouraging profile demonstrated against the isolated RT enzymes. |
| In Vivo | Lersivirine (oral gavage; 0, 150, 350, and 500 mg/kg; once daily; gestation days 6 to 17, followed by cesarean section on gestation day 18. ) allows induction of hepatic metabolizing enzymes at the first 2 days at 250 mg/kg, after which the dose is increased to 500 mg/kg/day in Mated Crl:CD1(ICR) mice. Lersivirine leads to skeletal variations which related to delayed development and decreased fetal ossifications. |
| PSA | 94.86000 |
| Target | IC50: 119 nM (NNRT) |
| Vapor Pressure | 0.0±1.2 mmHg at 25°C |
| XLogP3-AA | 2.1 |
